ES2367707T5 - Métodos para usar composiciones de aminopiridina de liberación sostenida - Google Patents

Métodos para usar composiciones de aminopiridina de liberación sostenida Download PDF

Info

Publication number
ES2367707T5
ES2367707T5 ES05732613T ES05732613T ES2367707T5 ES 2367707 T5 ES2367707 T5 ES 2367707T5 ES 05732613 T ES05732613 T ES 05732613T ES 05732613 T ES05732613 T ES 05732613T ES 2367707 T5 ES2367707 T5 ES 2367707T5
Authority
ES
Spain
Prior art keywords
methods
sustained release
release aminopyridine
aminopyridine compositions
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES05732613T
Other languages
English (en)
Other versions
ES2367707T9 (es
ES2367707T3 (es
Inventor
Andrew Blight
Lawrence Marinucci
Ron Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acorda Therapeutics Inc
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35061389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2367707(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Application granted granted Critical
Publication of ES2367707T3 publication Critical patent/ES2367707T3/es
Publication of ES2367707T9 publication Critical patent/ES2367707T9/es
Publication of ES2367707T5 publication Critical patent/ES2367707T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
ES05732613T 2004-04-09 2005-04-11 Métodos para usar composiciones de aminopiridina de liberación sostenida Active ES2367707T5 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US56089404P 2004-04-09 2004-04-09
US560894P 2004-04-09
US11/102,559 US8354437B2 (en) 2004-04-09 2005-04-08 Method of using sustained release aminopyridine compositions
US102559 2005-04-08
PCT/US2005/012427 WO2005099701A2 (en) 2004-04-09 2005-04-11 Methods of using sustained release aminopyridine compositions

Publications (3)

Publication Number Publication Date
ES2367707T3 ES2367707T3 (es) 2011-11-07
ES2367707T9 ES2367707T9 (es) 2012-07-05
ES2367707T5 true ES2367707T5 (es) 2024-04-25

Family

ID=35061389

Family Applications (2)

Application Number Title Priority Date Filing Date
ES11179067T Active ES2746354T3 (es) 2004-04-09 2005-04-11 Métodos de uso de composiciones de aminopiridina de liberación sostenida
ES05732613T Active ES2367707T5 (es) 2004-04-09 2005-04-11 Métodos para usar composiciones de aminopiridina de liberación sostenida

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES11179067T Active ES2746354T3 (es) 2004-04-09 2005-04-11 Métodos de uso de composiciones de aminopiridina de liberación sostenida

Country Status (21)

Country Link
US (13) US8354437B2 (es)
EP (5) EP1732548B2 (es)
JP (4) JP5736100B2 (es)
AT (1) ATE511841T1 (es)
AU (1) AU2005232732B2 (es)
CA (2) CA2870734C (es)
CY (4) CY1111754T1 (es)
DK (2) DK2377536T4 (es)
ES (2) ES2746354T3 (es)
FI (2) FI1732548T4 (es)
HK (1) HK1162971A1 (es)
HR (2) HRP20110497T4 (es)
HU (1) HUE046320T2 (es)
LU (2) LU91933I2 (es)
ME (2) ME01721B (es)
MX (3) MXPA06011648A (es)
PL (2) PL2377536T5 (es)
PT (2) PT1732548E (es)
RS (2) RS53371B2 (es)
SI (2) SI2377536T2 (es)
WO (1) WO2005099701A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007826B2 (en) * 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
AU2013206188B2 (en) * 2005-09-23 2016-04-14 Acorda Therapeutics, Inc. Method, apparatus and software for identifying responders in a clinical environment
US20100061935A1 (en) * 2008-09-10 2010-03-11 Acorda Therapeutics, Inc. Methods of using sustained release aminopyridine compositions
NZ595046A (en) * 2009-02-11 2013-10-25 Acorda Therapeutics Inc Compositions and methods for extended therapy with aminopyridines
JO3348B1 (ar) * 2009-08-11 2019-03-13 Acorda Therapeutics Inc استخدام 4- بايريدين امينو لتحسين الادراك العصبي و/او التلف النفسي لدى مرضى يعانون من نقص النُخاعين وغير ذلك من امراض الجهاز العصبي
TW201125562A (en) * 2009-09-04 2011-08-01 Acorda Therapeutics Inc Sustained release fampridine treatment in patients with multiple sclerosis
BR112013019265A2 (pt) * 2011-01-28 2016-10-11 Acorda Therapeutics Inc uso de bloqueadores do canal de potássio no tratamento da paralisia cerebral
US8924325B1 (en) * 2011-02-08 2014-12-30 Lockheed Martin Corporation Computerized target hostility determination and countermeasure
WO2013003708A1 (en) 2011-06-30 2013-01-03 Biomarin Pharmaceuticals, Inc. Methods of administering 3,4-diaminopyridine
TWI592156B (zh) 2011-10-04 2017-07-21 艾可達醫療公司 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
CA2864340A1 (en) 2012-02-13 2013-08-22 Acorda Therapeutics, Inc. Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine
WO2014028387A1 (en) 2012-08-13 2014-02-20 Acorda Therapeutics, Inc. Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine
WO2014093475A1 (en) 2012-12-11 2014-06-19 Acorda Therapeutics, Inc. Methods for treating parkinson's disease using aminopyridines
KR101814474B1 (ko) 2013-03-14 2018-01-12 엘커메스 파마 아일랜드 리미티드 푸마레이트의 프로드럭 및 다양한 질환을 치료하는데 있어서의 이들의 용도
US9993429B2 (en) * 2013-03-15 2018-06-12 University Of Rochester Composition and methods for the treatment of peripheral nerve injury
EP3427735A1 (en) 2013-04-15 2019-01-16 Acorda Therapeutics, Inc. Methods for treating sensorimotor impairments associated with certain types of stroke using aminopyridines
DK3253377T3 (da) 2015-02-08 2021-07-12 Alkermes Pharma Ireland Ltd Monomethylfumarat-prodrug-sammensætninger
RU2580837C1 (ru) * 2015-05-05 2016-04-10 Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Московский Физико-Технический Институт (Государственный Университет)" Кристаллогидрат 4-аминопиридина, способ его получения, фармацевтическая композиция и способ лечения и/или профилактики на её основе
US10172842B2 (en) 2015-09-11 2019-01-08 PharmaDax Inc. Sustained release oral dosage form containing dalfampridine
WO2018186866A1 (en) 2017-04-06 2018-10-11 Cobb Joseph E Jr Sustained release compositions of 4-aminopyridine
EP3355865A1 (en) 2015-09-29 2018-08-08 Acorda Therapeutics, Inc. Sustained release compositions of 4-aminopyridine

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1082804A (en) 1912-11-19 1913-12-30 Gerald G Griffin Confetti-machine.
US3065143A (en) 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
CH415963A (de) 1964-09-04 1966-06-30 Wander Ag Dr A Masse zur Herstellung von Tabletten mit protrahierter Wirkung
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4508715A (en) * 1981-07-01 1985-04-02 University Of Georgia Research Foundation, Inc. Antagonism of central nervous system drugs by the administration of 4-aminopyridine alone or in combination with other drugs
US4386095A (en) * 1982-02-22 1983-05-31 Cornell Research Foundation, Inc. Diaminopyridines to improve cognition
IE53703B1 (en) 1982-12-13 1989-01-18 Elan Corp Plc Drug delivery device
IE54286B1 (en) 1983-01-18 1989-08-16 Elan Corp Plc Drug delivery device
US4851230A (en) * 1983-04-07 1989-07-25 Bristol-Myers Company Capsule shaped tablets
IE56459B1 (en) 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
US4894240A (en) * 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US4562196A (en) 1984-04-06 1985-12-31 Nelson Research & Development 2,4-Diaminopyridine as a pharmacologic agent
JPS6124516A (ja) 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
US4812447A (en) 1985-10-22 1989-03-14 City Of Hope Method for the treatment of nervous system degeneration
US4760092A (en) 1985-10-29 1988-07-26 The Rockefeller University Treatment of demyelinating diseases
US4832957A (en) 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
IL86170A (en) * 1987-05-01 1992-12-01 Elan Transdermal Ltd Preparations and compositions comprising nicotine for percutaneous administration
IE64726B1 (en) 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
FI895821A0 (fi) * 1988-12-07 1989-12-05 Wellcome Found Farmaceutiskt aktiva cns foereningar.
US4948581A (en) 1989-02-17 1990-08-14 Dojin Iyaku-Kako Co., Ltd. Long acting diclofenac sodium preparation
IE82916B1 (en) 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
TW200462B (es) * 1990-09-27 1993-02-21 Hoechst Roussel Pharma
CA2085785C (en) 1992-12-18 2005-03-15 Robert R. Hansebout The use of 4-aminopyridine in the treatment of a neurological condition
DE4321030A1 (de) * 1993-06-24 1995-01-05 Bayer Ag 4-bicyclisch substituierte Dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimittel
US5451409A (en) 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5952357A (en) * 1993-12-23 1999-09-14 Cornell Research Foundation, Inc. Treating diseases of the anterior horn cells
US6284473B1 (en) * 1995-10-02 2001-09-04 Uab Research Foundation P-cresol sulfate, a component of urinary myelin basic protein-like material, as a correlate of multiple sclerosis status
US7179486B1 (en) 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
US6288026B1 (en) * 1999-02-24 2001-09-11 Heinrich Exner Process and composition for treating diseases with an oil-in-water emulsion
US6600399B1 (en) 2002-02-05 2003-07-29 Roland Pierre Trandafir Transducer motor/generator assembly
WO2004082684A1 (en) 2003-03-17 2004-09-30 Acorda Therapeutics Stable oral formulations of aminopyridines and uses thereof
AU2004226876A1 (en) * 2003-04-03 2004-10-14 Prana Biotechnology Ltd Treatment of neurological conditions
CA2534711A1 (en) * 2003-08-01 2005-02-10 Medarex, Inc. Combination therapies for multiple sclerosis
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
WO2006130726A2 (en) * 2005-06-01 2006-12-07 Teva Pharmaceutical Industries, Ltd. Use of ladostigil for the treatment of multiple sclerosis
AU2006292064A1 (en) 2005-09-23 2007-03-29 Acorda Therapeutics, Inc. Method, apparatus and software for identifying responders in a clinical environment
TWM331106U (en) * 2007-11-12 2008-04-21 Syspotek Corp Solution counter with temperature sensor
US20100061935A1 (en) 2008-09-10 2010-03-11 Acorda Therapeutics, Inc. Methods of using sustained release aminopyridine compositions
WO2010090730A1 (en) 2009-02-03 2010-08-12 Acorda Therapeutics, Inc. Method, apparatus and software for identifying responders in a clinical environment
NZ595046A (en) 2009-02-11 2013-10-25 Acorda Therapeutics Inc Compositions and methods for extended therapy with aminopyridines
JO3348B1 (ar) 2009-08-11 2019-03-13 Acorda Therapeutics Inc استخدام 4- بايريدين امينو لتحسين الادراك العصبي و/او التلف النفسي لدى مرضى يعانون من نقص النُخاعين وغير ذلك من امراض الجهاز العصبي
TW201125562A (en) 2009-09-04 2011-08-01 Acorda Therapeutics Inc Sustained release fampridine treatment in patients with multiple sclerosis
US10255905B2 (en) 2016-06-10 2019-04-09 Google Llc Predicting pronunciations with word stress

Also Published As

Publication number Publication date
MX370434B (es) 2019-12-13
EP2377536B1 (en) 2013-03-06
SI2377536T1 (sl) 2013-07-31
ES2746354T3 (es) 2020-03-05
DK1732548T4 (da) 2023-11-20
JP5736100B2 (ja) 2015-06-17
HRP20110497T4 (hr) 2024-03-29
US8440703B2 (en) 2013-05-14
EP2460521B1 (en) 2019-06-12
PL1732548T3 (pl) 2011-11-30
LU92275I9 (es) 2019-01-03
SI1732548T1 (sl) 2011-09-30
EP1732548B9 (en) 2012-03-21
CA2870734A1 (en) 2005-10-27
ES2367707T9 (es) 2012-07-05
JP2007532578A (ja) 2007-11-15
US20160199358A1 (en) 2016-07-14
ATE511841T1 (de) 2011-06-15
US20170071924A1 (en) 2017-03-16
EP2422782A1 (en) 2012-02-29
DK2377536T3 (da) 2013-03-25
JP2015157861A (ja) 2015-09-03
US20110166189A1 (en) 2011-07-07
CA2562277C (en) 2015-01-27
WO2005099701A3 (en) 2006-03-23
US20150080436A1 (en) 2015-03-19
RS53371B2 (sr) 2022-11-30
DK1732548T3 (da) 2011-09-26
PT2377536E (pt) 2013-04-11
US20170273960A1 (en) 2017-09-28
WO2005099701A2 (en) 2005-10-27
SI2377536T2 (sl) 2022-11-30
US20180200241A1 (en) 2018-07-19
CY2012004I1 (el) 2015-10-07
RS51808B2 (sr) 2023-12-29
RS51808B8 (sr) 2019-08-30
ME01721B (me) 2014-09-20
HUE046320T2 (hu) 2020-02-28
HRP20130424T1 (en) 2013-06-30
HRP20130424T4 (hr) 2022-10-28
AU2005232732B2 (en) 2011-05-12
ME01836B (me) 2014-12-20
MX2019015036A (es) 2020-02-24
HRP20110497T1 (hr) 2011-08-31
PL2377536T5 (pl) 2023-03-06
PL2377536T3 (pl) 2013-08-30
LU92275I2 (fr) 2015-09-03
CY2013035I1 (el) 2020-05-29
JP5914626B2 (ja) 2016-05-11
US8354437B2 (en) 2013-01-15
HK1162971A1 (en) 2012-09-07
US20170209422A1 (en) 2017-07-27
MXPA06011648A (es) 2008-10-31
EP1732548B2 (en) 2023-08-30
RS53371B (en) 2014-10-31
CY1114073T1 (el) 2016-07-27
RS51808B9 (sr) 2019-06-28
US20110166187A1 (en) 2011-07-07
CY2012004I2 (el) 2015-10-07
US20120064007A1 (en) 2012-03-15
JP2012188427A (ja) 2012-10-04
CY1111754T1 (el) 2015-10-07
US20140039015A1 (en) 2014-02-06
US20120164078A1 (en) 2012-06-28
PL1732548T4 (pl) 2012-03-30
PT1732548E (pt) 2011-09-16
EP1732548A2 (en) 2006-12-20
EP2377536A1 (en) 2011-10-19
US20110166188A1 (en) 2011-07-07
EP3922248A1 (en) 2021-12-15
JP2015057451A (ja) 2015-03-26
AU2005232732A1 (en) 2005-10-27
US20050228030A1 (en) 2005-10-13
FIC20130042I1 (fi) 2013-08-13
DK2377536T4 (da) 2022-11-07
EP2460521A1 (en) 2012-06-06
EP2377536B2 (en) 2022-08-17
LU91933I2 (fr) 2013-01-18
EP1732548B1 (en) 2011-06-08
FI1732548T4 (fi) 2023-11-30
CA2562277A1 (en) 2005-10-27
CA2870734C (en) 2022-08-16
SI1732548T2 (sl) 2024-02-29
RS51808B (en) 2011-12-31
US9925173B2 (en) 2018-03-27
EP1732548A4 (en) 2009-06-03
ES2367707T3 (es) 2011-11-07

Similar Documents

Publication Publication Date Title
ES2367707T5 (es) Métodos para usar composiciones de aminopiridina de liberación sostenida
FR22C1008I2 (fr) Composition immunogène
DK1954241T3 (da) Zonisamid-formulering med vedvarende frigivelse
DE602006011787D1 (de) Ker
DE602005020968D1 (de) n dafür
ITMI20041252A1 (it) Composizioni perfluoroelastomeriche
ATE553079T1 (de) Heteroarylphenylharnstoffderivat
BRPI0819911A2 (pt) composições compreendendo agonistas nicotínicos e métodos para usar as mesmas
DE602005016978D1 (de) Quecksilberfreisetzende Zusammensetzungen
AT503451B8 (de) Festkörperlaser
DE602005017191D1 (de) Geruchsreduzierte waschstück-zusammensetzung
FI20055364A (fi) Aikasynkronointi
ATE452628T1 (de) Anthelminthische zusammensetzung
DE502005001935D1 (de) Festkörperlaser
FR2871686B1 (fr) Composition anti-decoloration
ES1061541Y (es) Bloques para la construccion
DE112004002869A5 (de) Überlastauslöser
FI20040247A0 (fi) Kaavin
ES1060279Y (es) Baculo para semaforos
ES1056978Y (es) Mastil para banderines
FI6255U1 (fi) Pikakiinnitysmekanismi
ES1059344Y (es) Tahali para porras
EE04943B1 (et) Biolaguneva pindaktiivse puhastusvahendi kompositsioon
GB0504714D0 (en) Method for patterning solid surfaces
NO20043762L (no) Fôr